|
|
Vision Sciences and ESTECH Announce Distribution AgreementProducts for Minimally Invasive Cardiac Surgery in the Treatment of Atrial FibrillationNATICK, Mass., June 2 /PRNewswire-FirstCall/ -- Vision-Sciences, Inc., (Nasdaq: VSCI) announced today the signing of a Development, Supply and Distribution Agreement (the "Agreement") with ESTECH, Inc. (privately held) of Danville, CA, for products designed to provide access and visualization for minimally invasive cardiac surgery for the treatment and ablation of atrial fibrillation.According to Medtech Insight, Atrial Fibrillation (AF) affects more than two million people in the US and six million people worldwide, and "is responsible for one-third of all hospitalizations related to cardiac rhythm disorders (over 360,000 per year), resulting in billions of dollars in healthcare expenditures." The Vision Sciences CT-F100 and CTSS-F21 Cardiothoracic Endoscope and Slide-On(TM) EndoSheath(R) System is designed to provide minimally invasive access to the pericardium in order to enhance visualization during epicardial AF ablation procedures. Under the Agreement, ESTECH will distribute the CT- F100 and CTSS-F21 with its suite of products for AF ablation. ESTECH has exclusive rights for the distribution of the CT-F100 and CTSS-F21 within the field of minimally invasive cardiac AF ablation surgery, contingent upon meeting certain terms and conditions. "We are excited by the opportunity to introduce the EndoSheath technology to the field of minimally invasive AF surgery, and to have ESTECH as our marketing partner in this endeavor. We believe the combination of ESTECH's demonstrated leadership in the minimally invasive Cardiac Surgery arena, combined with the proven benefits of our EndoSheath technology, will provide significant benefits to patients and surgeons in this important emerging treatment," stated Ron Hadani, President and CEO of Vision-Sciences, Inc. ESTECH CEO Art Bertolero stated, "We are very pleased to be able to offer the Vision Sciences CardioThoracic EndoSheath products to our expanding base of customers, and we look forward to a long and fruitful relationship." Vision-Sciences, Inc. develops, manufactures and markets unique flexible endoscopic products utilizing sterile disposable sheaths (the EndoSheath(R) system) which provide the users quick, efficient product turnover while ensuring the patient a contaminant-free product. Information about the Company's products is available on the internet at http://www.Endosheath.com, and Company information is available at http://www.visionsciences.com. ESTECH, Inc., founded in 1996, is a privately held company with headquarters in San Ramon, California. ESTECH is a recognized leader in Least Invasive Cardiac Surgery (LICS), offering a complete system of products for both beating heart and stopped heart surgical approaches. ESTECH has training, product support and distribution in the United States and Europe. Further information on ESTECH is available at http://www.estech.com. Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. Future results may vary significantly based on a number of factors including, but not limited to, risks in market acceptance of new products and services and continuing demand for same, the impact of competitive products and pricing, seasonality, changing economic conditions and other risk factors detailed in the Company's most recent annual report and other filings with the Securities and Exchange Commission.
SOURCE Vision-Sciences, Inc. Web Site: http://www.visionsciences.com -------------------------------------------------------------------------------- Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content. Copyright c 1996-2002 PR Newswire Association LLC. All Rights Reserved. A United Business Media company. Back to News |
|||